Quest Diagnostics Inc. stock falls 2.94% amid broad market downturn

4 articles · Updated · MarketWatch · Apr 29

Shares closed at $189.32, marking a second consecutive day of losses and trading 11.33% below the 52-week high.
Quest Diagnostics underperformed competitors, with UnitedHealth Group rising 1.08% and Centene Corp. surging 8.90%, while trading volume reached 1.4 million, surpassing the 50-day average.
The decline occurred during a generally negative session for the S&P 500 and Dow Jones, reflecting wider market pressures impacting healthcare stocks.

Why did Quest's stock plummet despite the company reporting record-breaking earnings?

Will rising costs and new projects derail Quest's impressive growth streak?

How does Quest plan to win against rivals surging ahead in the market?

Can Quest's new AI-powered health assistant truly revolutionize patient care?

Are company insiders selling their shares because they foresee future trouble?